Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis
J F Colombel(European CanCer Organisation), William J. Sandborn(University of San Diego), Walter Reinisch(Medical University of Vienna), Peter G. Gibson(University Gastroenterology), H. Zhang(Janssen (United States)), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), P. Rutgeerts, Judith Collins(Oregon Health & Science University), Chenglong Han(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center)
Cited by 0
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k